ArriVent BioPharma, Inc. AVBP Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $129.68M-15.4% | $153.35M+8.5% | $141.34M+9.3% | $129.26M+4.8% | $123.32M+56.1% | ||
| $27.19M+12.5% | $24.18M+14.7% | $21.08M+10.5% | $19.07M+11.6% | $17.09M+11.7% | ||
| $156.87M-11.6% | $177.53M+9.3% | $162.42M+9.5% | $148.33M+5.6% | $140.41M+48.9% | ||
| -$156.87M+11.6% | -$177.53M-9.3% | -$162.42M-9.5% | -$148.33M-5.6% | -$140.41M-48.9% | ||
| -$145.24M+12.7% | -$166.31M-9.8% | -$151.4M-10.5% | -$136.98M-7.5% | -$127.46M-58.4% | ||
| -$3.47+21.3% | -$4.41-4.0% | -$4.24-5.5% | -$4.02-6.6% | -$3.77-46.7% | ||
| -$159.7M+11.6% | -$180.56M— | —— | —— | —— | ||
| -$156.87M+11.6% | -$177.53M-9.3% | -$162.42M-9.5% | -$148.33M-5.6% | -$140.41M-48.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is ArriVent BioPharma, Inc. profitable?
- ArriVent BioPharma, Inc. is not currently profitable: it reported a net loss of $145.2M over the trailing twelve months.
- What is ArriVent BioPharma, Inc.'s earnings per share?
- ArriVent BioPharma, Inc.'s diluted EPS over the trailing twelve months is $-3.47.
- Where does ArriVent BioPharma, Inc.'s income statement data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.